PBSO further gives a reduction in ovarian cancer specific mortality of 95% and in breast cancer specific mortality of 42% [[34], [35], [36], [37], [38]] The risk reduction in breast cancer is more pronounced for BRCA1 mutation carriers than BRCA2 mutation carriers [34]. This evidence concerns the gene BRCA2 and ovarian carcinoma.